Key Points
- Jonathan Gillis sold 17,935 Maplight shares on April 28 at an average of $30.35 for $544,327 and previously sold 51,900 shares on April 27, with the transactions executed under a pre-arranged Rule 10b5-1 plan and leaving him with 181,219 shares (a 9.01% ownership reduction).
- Maplight shares trade near $30.29 with a 12‑month range of $12.24–$33.28 and a $1.29B market cap; the company reported a sizable EPS miss (loss of $2.47 vs. $1.05 expected) while analysts remain mixed but show a consensus rating of Moderate Buy and a $32.67 price target.
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) insider Jonathan Gillis sold 17,935 shares of Maplight Therapeutics stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $30.35, for a total transaction of $544,327.25. Following the completion of the sale, the insider owned 181,219 shares in the company, valued at approximately $5,499,996.65. This represents a 9.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jonathan Gillis also recently made the following trade(s):
- On Monday, April 27th, Jonathan Gillis sold 51,900 shares of Maplight Therapeutics stock. The shares were sold at an average price of $29.74, for a total transaction of $1,543,506.00.
Maplight Therapeutics Trading Down 0.1%
Shares of Maplight Therapeutics stock opened at $30.29 on Thursday. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $33.28. The firm's 50-day moving average price is $21.91. The stock has a market capitalization of $1.29 billion and a price-to-earnings ratio of -0.76.
Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported ($2.47) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by ($1.42). Sell-side analysts forecast that Maplight Therapeutics, Inc. will post -3.87 earnings per share for the current fiscal year.
Analysts Set New Price Targets
MPLT has been the topic of several recent research reports. Weiss Ratings initiated coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They set a "sell (e)" rating on the stock. Wall Street Zen lowered shares of Maplight Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 21st. Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They issued a "buy" rating and a $35.00 price target on the stock. TD Cowen started coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They set a "buy" rating on the stock. Finally, Needham & Company LLC assumed coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They set a "buy" rating and a $37.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $32.67.
View Our Latest Analysis on Maplight Therapeutics
Institutional Investors Weigh In On Maplight Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MPLT. Strs Ohio bought a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Maplight Therapeutics during the 4th quarter valued at approximately $70,000. New York State Common Retirement Fund bought a new position in shares of Maplight Therapeutics during the 4th quarter valued at approximately $93,000. MetLife Investment Management LLC purchased a new stake in Maplight Therapeutics during the 4th quarter valued at $172,000. Finally, Walleye Capital LLC bought a new stake in Maplight Therapeutics in the fourth quarter worth $205,000.
Maplight Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
